Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III study of Omadacycline for community-acquired bacterial pneumonia (CABP)

Next Previous
Trial Profile

A phase III study of Omadacycline for community-acquired bacterial pneumonia (CABP)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 04 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omadacycline (Primary)
  • Indications Bacterial infections; Community-acquired pneumonia
  • Focus Registrational; Therapeutic Use
  • Sponsors Paratek Pharmaceuticals

Most Recent Events

  • 27 Apr 2020 Results published in the Antimicrobial Agents and Chemotherapy
  • 25 Oct 2019 New trial record
  • 17 Oct 2019 According to a Paratek Pharmaceuticals media release, the company has agreed this post-marketing approval study for community-acquired bacterial pneumonia (CABP) with FDA. The EMA has requested this study in CABP to meet regulatory standards of two Phase 3 studies.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top